Crinetics Pharmaceuticals (FRA:6Z4) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Z4 Crinetics Pharmaceuticals Inc FRA:6Z4
50 GF Score
Price €70.90
GF Value €626.58
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Crinetics Pharmaceuticals Valuation Rank Related Terms

FRA:6Z4
50GF Score
Crinetics Pharmaceuticals Inc FRA:6Z4
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €626.58. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:6Z4:

  • Valuation Rank:
  • GF Value™: €626.58 vs. price of €70.90 (88.7% below fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges CRNX:USA
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score

Get the complete analysis for FRA:6Z4

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.90
Price
€626.58
GF Value